For the Inventor, By the Inventor

Enter assignee name

Horsham, PA, United States of America

Cell Pathways

USPTO Granted Patents = 75

% Expired Patents = 13.3

Forward Citations = 807

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Rifat Pamukcu (67 out of 74 patents)

Gary A Piazza (54 out of 58 patents)

Gerhard J Sperl (22 out of 24 patents)

4. Paul Gross (17 out of 19 patents)

5. Klaus Brendel (16 out of 21 patents)

6. W Joseph Thompson (7 out of 8 patents)

7. Kerstin B Menander (6 out of 8 patents)

8. Han Li (4 out of 15 patents)

9. Li Liu (3 out of 3 patents)

10. Ulrich Ixkes (3 out of 3 patents)

11. Xiaojing Michael Wang (2 out of 12 patents)

12. Hector W Alila (2 out of 4 patents)

13. Keith A Earle (2 out of 3 patents)

14. Clark M Whitehead (2 out of 2 patents)

15. Mark Jeffrey Mayle (2 out of 2 patents)

Core Competencies:

Neoplasia

Cancer Treatment

Renal Cell Carcinoma

Precancerous Lesions

Pharmaceutical Compositions

Vinca Alkaloids

Isoquinoline Derivatives

Benzimidazole Derivatives

Purin-6-Ones

Phenyl Quinazolinone

Paclitaxel Derivatives

Indole Derivatives

75 patents: Sort by Forward Citations

1. 6569638 - Method for screening compounds for the treatment of neoplasia (2003-05-27),

2. 6562830 - Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives (2003-05-13),

3. 6555547 - Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative (2003-04-29),

4. 6538029 - Methods for treatment of renal cell carcinoma (2003-03-25),

5. 6500610 - Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds (2002-12-31),

6. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia (2002-11-26),

7. 6486155 - Method of inhibiting neoplastic cells with isoquinoline derivatives (2002-11-26),

8. 6479520 - Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives (2002-11-12),

9. 6479493 - Methods for treatment of type I diabetes (2002-11-12),

10. 6472420 - Method for treating a patient with neoplasia by treatment with a paclitaxel derivative (2002-10-29),

11. 6465494 - Methods for treatment of cystic fibrosis (2002-10-15),

12. 6455703 - 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia (2002-09-24),

13. 6440981 - Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones (2002-08-27),

14. 6432950 - Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives (2002-08-13),

15. 6420410 - Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones (2002-07-16),

Cell Pathways, based in Horsham, PA, specializes in the development of innovative treatments for neoplasia, focusing on various forms of cancer, including renal cell carcinoma and precancerous lesions. The company is dedicated to advancing pharmaceutical compositions that leverage the therapeutic potential of vinca alkaloids, isoquinoline derivatives, and benzimidazole derivatives. Through its research, Cell Pathways aims to provide effective solutions that enhance patient outcomes in oncology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

75 Patents

#4 in Horsham, PA

#185 in Pennsylvania

#4,900 in US

#9,996 in the World

Horsham, PA, United States of America

Cell Pathways

Forward Citations = 807

22 inventors:

Rifat Pamukcu (67 out of 74 patents)

Gary A Piazza (54 out of 58 patents)

Gerhard J Sperl (22 out of 24 patents)

4. Paul Gross (17 out of 19 patents)

5. Klaus Brendel (16 out of 21 patents)

Please report any incorrect information to [email protected]

Loading…